Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors

Health and Quality of Life Outcomes

Jeong Hoon Kim²  Yong Soon Shin¹ 

[1]Department of Nursing, Changwon National University, 92 Toechonro, Uichang-gu, Changwon, Gyeongnam 641-773, South Korea

[2]Department of Neurology Surgery, University of Ulsan College of Medicine, Asan Medical Center, Asanbyeongwon-gil 86, Songpa-gu, Seoul 138-736, South Korea

关键词: Korea;    Validation;    QLQ-C30;    QLQ-BN20;    Health-related quality of life;    Brain tumor;   

Others  :  823289
DOI  :  10.1186/1477-7525-11-145

 received in 2013-02-14, accepted in 2013-08-06,  发布年份 2013

【 摘 要 】

Background

The European Organization for Research and Treatment of Cancer Quality of Life Brain Cancer Module has been translated into Korean, but to date, its reliability and validity have been evaluated in a pilot study alone. The European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire is, overall, a valid instrument to assess the health-related quality of life in Korean cancer patients, although its reliability and validity have not yet been evaluated in patients with brain tumors. This study aimed at evaluating the psychometric properties of these instruments in patients with brain tumors.

Findings

The 2 instruments were used for 307 Korean patients with brain tumors. Multi-trait scaling confirmed the scale structure of the instruments with good item convergent and discriminant validity. The reliability was acceptable for all scales except for cognitive functioning and nausea and vomiting. The instruments could be used to distinguish between clinically distinct groups of patients.

Conclusions

The study findings indicate that the instruments are valid and suitable for the assessment of the health-related quality of life in patients with brain tumors as well as in those with primary brain cancer.

【 授权许可】

   
2013 Shin and Kim; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E: The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 1996, 5:139-150.
• [2]List of translations available by language – validated modules and C30. http://groups.eortc.be/qol/sites/default/files/img/sidebar/validated_modules_by_june.pdf?width=900&height=700&iframe=true webcite
• [3]Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, You CH, West K: Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res 2004, 13:863-868.
• [4]Taphoorn MJ, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, Stupp R, Mirimanoff RO, Van den Bent MJ, Bottomley A: An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer 2010, 46:1033-1040.
• [5]Aaronson NK, Taphoorn MJ, Heimans JJ, Postma TJ, Gundy CM, Beute GN, Slotman BJ, Klein M: Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol 2011, 29:4430-4435.
• [6]Khoshnevisan A, Yekaninejad MS, Ardakani SK, Pakpour AH, Mardani A, Aaronson NK: Translation and validation of the EORTC brain cancer module (EORTC QLQ-BN20) for use in Iran. Health Qual Life Outcomes 2012, 10:54. BioMed Central Full Text
• [7]Carrillo JF, Ortiz-Toledo MA, Salido-Noriega Z, Romero-Ventura NB, Ochoa-Carrillo FJ, Onate-Ocana LF: Validation of the Mexican Spanish version of the EORTC QLQ-H&N35 instrument to measure health-related quality of life in patients with head and neck cancers. Ann Surg Oncol 2012, 20(5):1417-1426.
• [8]Cerezo O, Onate-Ocana LF, Arrieta-Joffe P, Gonzalez-Lara F, Garcia-Pasquel MJ, Bargallo-Rocha E, Vilar-Compte D: Validation of the Mexican-Spanish version of the EORTC QLQ-C30 and BR23 questionnaires to assess health-related quality of life in Mexican women with breast cancer. Eur J Cancer Care (Engl) 2012, 21:684-691.
• [9]Kontodimopoulos N, Ntinoulis K, Niakas D: Validity of the Greek EORTC QLQ-C30 and QLQ-BR23 for measuring health-related quality of life in breast cancer patients. Eur J Cancer Care (Engl) 2011, 20:354-361.
• [10]Onate-Ocana LF, Alcantara-Pilar A, Vilar-Compte D, Garcia-Hubard G, Rojas-Castillo E, Alvarado-Aguilar S, Carrillo JF, Blazeby JM, Aiello-Crocifoglio V: Validation of the Mexican Spanish version of the EORTC C30 and STO22 questionnaires for the evaluation of health-related quality of life in patients with gastric cancer. Ann Surg Oncol 2009, 16:88-95.
• [11]Kobayashi K, Takeda F, Teramukai S, Gotoh I, Sakai H, Yoneda S, Noguchi Y, Ogasawara H, Yoshida K: A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer 1998, 34:810-815.
• [12]Cheng JX, Liu BL, Zhang X, Zhang YQ, Lin W, Wang R, Zhang HY, Xie L, Huo JL: The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China. BMC Med Res Methodol 2011, 11:56. BioMed Central Full Text